Loading patent…
AssigneesCharite-Universitatsmedizin Berlin, Technische UniversitäT Berlin
InventorsHenry Fechner, Geisler Anja
Estimating the term…
The present invention is directed to an isolated miR-206 target site, comprising or consisting of a nucleic acid sequence with a sequence identity of at least 80% compared to wild type miR-206 target site with SEQ ID No. 1, characterized in that the nucleic acid sequence comprises at least one nucleotide substitution at a position from nucleotide 2 to 8 and/or at least one nucleotide substitution at a position from nucleotide 12 to 16 of SEQ D No. 1, wherein the nucleotide positions of SEQ ID No. 1 are numbered from the 3′- to the 5′-end; as well as to an expression cassette, vector and pharmaceutical composition comprising at least one isolated miR-206 target site of the invention.
Isolated miR-206 target site, comprising or consisting of a nucleic acid sequence with a sequence identity of at least 80% compared to wild type miR-206 target site with SEQ ID No. 1, characterized in that the nucleic acid sequence comprises at least one nucleotide substitution at a position from nucleotide 2 to 8 and/or at least one mutation at a position from nucleotide 12 to 16 of SEQ D No. 1, wherein the nucleotide positions of SEQ ID No. 1 are numbered from the 3′- to the 5′-end.
Isolated miR-206 target site of one of the preceding claims, comprising or consisting of a nucleic acid sequence of SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12, SEQ ID No. 13, SEQ ID No. 14, SEQ ID No. 15 or SEQ ID No. 22.
Dependencies are inferred from the claim text.